IPSEN – Buy-back programme – Art 5 of MAR – Week 22 – 2026
Aggregated presentation by day and by market
| Purchases of own shares from May 25th to May 29th 2026 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 25/05/2026 | FR0010259150 | 3 000 | 161,8079 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 26/05/2026 | FR0010259150 | 3 500 | 160,9287 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 27/05/2026 | FR0010259150 | 4 000 | 159,3918 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 28/05/2026 | FR0010259150 | 4 500 | 156,1991 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 29/05/2026 | FR0010259150 | 5 411 | 155,8712 | XPAR |
| TOTAL | 20 411 | 158,3732 | ||||
Attachment

IPSEN – Buy-back programme – Art 5 of MAR – Week 22 – 2026
Aggregated presentation by day and by market
| Purchases of own shares from May 25th to May 29th 2026 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 25/05/2026 | FR0010259150 | 3 000 | 161,8079 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 26/05/2026 | FR0010259150 | 3 500 | 160,9287 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 27/05/2026 | FR0010259150 | 4 000 | 159,3918 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 28/05/2026 | FR0010259150 | 4 500 | 156,1991 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 29/05/2026 | FR0010259150 | 5 411 | 155,8712 | XPAR |
| TOTAL | 20 411 | 158,3732 | ||||
Attachment

Related stories
Quand les acides biliaires prennent une dimension plus large : comment la biologie de la cholestase transforme la recherche sur les maladies hépatiques rares
Tester l’hypothèse : un pilote ciblé sur l’IA dans le domaine de la santé
Toujours une longueur d’avance : Anne Petit et l’art de concrétiser les médicaments
Related Press Releases
Ipsen provides update on Phase III BOLD trial in biliary...
Ipsen – Corrective statement amending the monthly disclosure of the...
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2026 – Monthly information relative to the...
Ipsen – Half year statement – 2026 06 30
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...